Loading stock data…
$0.87-0.03 (-3.05%)
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
Aldeyra Therapeutics, Inc. in the Healthcare sector is trading at $0.87 with a market capitalization of $89M. Wall Street consensus targets $6.60 (5 analysts), implying a +656.5% move over the next 12 months. The stock is currently near its 52-week low of $0.86, remaining 65.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.85M↓ | -$3.55M↑ | -$6.67M↑ | -$8.00M↑ | -$10.17M |
| Net Income | -$5.45M↓ | -$3.45M↑ | -$6.46M↑ | -$7.69M↑ | -$9.77M |
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical t...